poteligeo 4 mgml
medison pharma ltd - mogamulizumab - concentrate for solution for infusion - mogamulizumab 4 mg / 1 ml - mogamulizumab - poteligeo is indicated for the treatment of adult patients with mycosis fungoides (mf) or sézary syndrome (ss) who have received at least one prior systemic therapy.
poteligeo- mogamulizumab-kpkc injection
kyowa kirin, inc. - mogamulizumab (unii: yi437801be) (mogamulizumab - unii:yi437801be) - poteligeo is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (mf) or sézary syndrome (ss) after at least one prior systemic therapy. none. risk summary there are no available data on poteligeo use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. in an animal reproduction study, administration of mogamulizumab-kpkc to pregnant cynomolgus monkeys from the start of organogenesis through delivery did not show a potential for adverse developmental outcomes at maternal systemic exposures 27 times the exposure in patients at the recommended dose, based on auc (see data ). in general, igg molecules are known to cross the placental barrier and in the monkey reproduction study mogamulizumab-kpkc was detected in fetal plasma. therefore, poteligeo has the potential to be transmitted from the mother to the developing fetus. poteligeo is not recommended during pregnancy or in women of childbearing potential not using contraception. the es
poteligeo
kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - antineoplastic agents - poteligeo is indicated for the treatment of adult patients with mycosis fungoides (mf) or sézary syndrome (ss) who have received at least one prior systemic therapy.
poteligeo solution
kyowa kirin, inc. - mogamulizumab - solution - 4mg - mogamulizumab 4mg
poteligeo mogamulizumab 4 mg/ml concentrate for solution for infusion vial
kyowa kirin australia pty ltd - mogamulizumab, quantity: 20 mg - injection, intravenous infusion - excipient ingredients: citric acid monohydrate; glycine; polysorbate 80; sodium hydroxide; hydrochloric acid; water for injections - poteligeo is indicated for the treatment of adult patients (18 years of age and above) with mycosis fungoides (mf) or s?zary syndrome (ss) who have received at least one prior systemic therapy
poteligeo concentrate for solution for infusion
kyowa kirin holdings b.v., netherlands - mogamulizumab - concentrate for solution for infusion - 4 mg/ml
poteligeo injection (ポテリジオ点滴静注20mg)
kyowa kirin co.,ltd - mogamulizumab(genetical recombination) - injection